The Leukemia & Lymphoma Society (LLS) is proud of our long history of supporting the work of Brian Druker, M.D., Director of OHSU Knight Cancer Institute, Oregon Health and Science University. Druker is a world-renowned researcher with a proven track record of success in revolutionizing the treatment of patients with chronic myeloid leukemia (CML). Early on LLS saw the potential of Druker’s pioneering work, and invested at a time when others were skeptical of taking a risk on a drug with limited market size. LLS funded his early breakthrough studies proving the anti-leukemia activity of a novel enzyme inhibitor now known as Gleevec®, and later the clinical trials that led to the accelerated FDA approval of the drug that is now that is now saving countless lives of patients with CML and helping patients with other cancers as well. In recent years Druker has turned his attention to AML and other types of leukemia, and through our Specialized Center of Research program, LLS has continued to support his work.
LLS features Druker in this video, posted on the LLS.org video gallery, in which he talks about how the early funding from LLS helped him at a critical juncture in his research, when he was trying to translate a laboratory discovery to clinical application. Druker concludes by saying that when people ask him where they should donate their money his answer is simple: “The Leukemia & Lymphoma Society is the best investment of your funds; LLS is making an impact and accelerating progress.”
The video can also be viewed on our YouTube Chanel.